arrow
F

Faith E. Davies

perlmutter cancer centre
H指数:98
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma

IMiD治疗的多发性骨髓瘤患者动脉血栓栓塞的临床、细胞遗传学和胚系遗传决定因素

2026-09-240
OA
REVEAL-MM: retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma—a US claims-based case-control study

REVEAL-MM:多发性骨髓瘤早期评估和里程碑趋势中变量的回顾性评估——一项基于美国索赔数据的病例对照研究

2026-09-140
OAAI
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis

PI-Rd三联疗法在复发/难治性多发性骨髓瘤中的疗效与安全性比较:INSIGHT-MM数据分析

2026-01-010
OAAI
Temporal genomic dynamics shape clinical trajectory in multiple myeloma

时间基因组动力学塑造多发性骨髓瘤的临床轨迹

2025-08-200
OA
A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

对华氏巨球蛋白血症的多组学分析确定了独特的疾病亚型

Blood
IF23.1
2025-05-110
PRE
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

无进展生存期作为骨髓瘤临床试验的替代终点: 一个不断发展的范式

2024-08-121
OAAI
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

关于多发性骨髓瘤先兆临床试验优化设计的圆桌讨论

2024-05-012
OA
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
2023-11-098
PRE
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

来那度胺在新诊断的符合移植条件和不符合移植条件的骨髓瘤患者中的维持治疗; 在骨髓瘤XI试验中治疗的4358例患者中分析第二原发性恶性肿瘤

2023-08-015
OAAI